VÝVOJ LÉČBY POKROČILÉHO NEMALOBUNĚČNÉHO KARCINOMU PLIC (NSCLC) V ČESKÉ REPUBLICE (ČR)

• Title in English: The development of advanced non-small cell lung cancer (NSLC) treatment in the Czech Republic
• Authors: SKŘIČKOVÁ Jana; BORTLÍČEK Zbyněk; HEJDUK Karel; PEŠEK M.; ZATLOUKAL P.; KOLEK V.; SALAJKA F.; KOUBKOVÁ L.; TOMÍŠKOVÁ Marcela; GRYGÁRKOVÁ Y.; HAVEL L.; HRNČIARIK M.; ZEMANOVÁ M.; SIXTOVÁ D.; ROUBEC J.; ČOUPKOVÁ H.; KOŠATOVÁ K.
• Year of publication: 2013
• Type: Conference abstract
• MU Faculty or unit: Faculty of Medicine
• Description: Based on the TULUNG register, data of 2,911 NSCLC patients treated with erlotinib, gefitinib, bevacizumab a pemetrexed are analysed. Patients treated with erlotinib had median survival 7.4 months, those with bevacizumab 17.5 months, pemetrexed combined with cisplatin 11.6 months.